Narcolepsy-Pipeline Insights, 2017

DelveInsights, Narcolepsy-Pipeline Insights, 2017, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Narcolepsy. This report provides information on the therapeutic development based on the Narcolepsy dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Pre-Clinical, Discovery and Unknown stages, therapeutics assessment by mono-therapy and combination products and molecule type drug information. The report also covers the companys information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.
Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Narcolepsy Overview
Pipeline Therapeutics
Therapeutics under Development by Companies
Late Stage Products (Phase III)
Mid Stage Products (Phase II)
Early Stage Products (Phase I)
Pre-Clinical Products
Discovery Products
Unknown Phase Products
Therapeutic Assessment
Assessment by Mono-therapy Products
Assessment by Combination Therapy Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Dormant Products
Discontinued Products
Companies Involved in Therapeutic Development
Appendix
Consulting Services
About DelveInsight
Contact Us
Disclaimer

List Of Tables

Table 1: Number of Products Under Development for Narcolepsy
Table 2: Number of Products under Development by Companies
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and discovery Products
Table 7: Discovery Products
Table 8: Unknown Phase Products
Table 9: Assessment by Monotherapy Products
Table 10: Assessment by Combination Therapy Products
Table 11: Assessment by Route of Administration
Table 12:Assessment by Stage and Route Of Administration
Table 13: Assessment by Molecule Type
Table 14: Assessment by Stage and Molecule Type
Table 15: Dormant Products
Table 16: Discontinued Products
Table 17: Avadel Pharmaceuticals
Table 18: Balance Therapeutics Inc.
Table 19: Heptares Therapeutics Limited
Table 20: Jazz Pharmaceuticals PLC
Table 21: NLS Pharma
Table 22: ONO Pharmaceutical Co. Ltd.
Table 23: Reset Therapeutics
Table 24: Taisho Pharmaceutical Co., Ltd.
Table 25: Theranexus

List Of Figures

Figure 1: Number of Products under Development for Narcolepsy
Figure 2: Late Stage Products (Phase III)
Figure 3: Mid Stage Products (Phase II)
Figure 4: Early Stage Products (Phase I)
Figure 5: Pre-clinical and discovery Products
Figure 6: Discovery Products
Figure 7: Unknown Phase Products
Figure 8: Assessment by Mono-therapy Products
Figure 9: Assessment by Combination Therapy Products
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Dormant Products
Figure 15: Discontinued Products

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available